Tempest Therapeutics, Inc. Operating Expenses
Tempest Therapeutics, Inc. (TPST) reported Operating Expenses of $5.95 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2018-11-09
- Tempest Therapeutics, Inc. operating expenses for the quarter ending 2018-09-30 was $5.95M, a 37.09% decline year-over-year.
- Tempest Therapeutics, Inc. operating expenses for the quarter ending 2018-06-30 was $7.99M, a 55.67% decline year-over-year.
- Tempest Therapeutics, Inc. operating expenses for the quarter ending 2018-03-31 was $7.65M, a 47.79% decline year-over-year.
- Tempest Therapeutics, Inc. operating expenses for the quarter ending 2017-12-31 was $8.78M, a 60.98% decline year-over-year.
- Tempest Therapeutics, Inc. operating expenses for fiscal 2017 was $50.90M, a 37.67% decline from fiscal 2016.
- Tempest Therapeutics, Inc. operating expenses for fiscal 2016 was $81.67M, a 12.99% increase from fiscal 2015.
- Tempest Therapeutics, Inc. operating expenses for fiscal 2015 was $72.28M, a 50.79% increase from fiscal 2014.
- Tempest Therapeutics, Inc. operating expenses for fiscal 2014 was $47.93M, a 64.53% increase from fiscal 2013.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month | Operating Expenses 15 month | Operating Expenses 18 month | Operating Expenses 21 month | Operating Expenses 24 month | Operating Expenses 27 month | Operating Expenses 30 month | Operating Expenses 33 month | Operating Expenses 36 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-09-30 | $5.95M 10-Q · filed 2018-11-09 | $13.94M derived: sum of 2 quarters · filed 2018-11-09 | $21.59M 10-Q · filed 2018-11-09 | $30.36M derived: sum of 4 quarters · filed 2018-11-09 | ||||||||
| 2018-06-30 | $7.99M 10-Q · filed 2018-08-09 | $15.63M 10-Q · filed 2018-08-09 | $24.41M derived: sum of 3 quarters · filed 2018-08-09 | $33.87M derived: sum of 4 quarters · filed 2018-11-09 | ||||||||
| 2018-03-31 | $7.65M 10-Q · filed 2018-05-03 | $16.42M derived: sum of 2 quarters · filed 2018-05-03 | $25.89M derived: sum of 3 quarters · filed 2018-11-09 | $43.90M derived: sum of 4 quarters · filed 2018-11-09 | ||||||||
| 2017-12-31 | $8.78M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $18.24M derived: sum of 2 quarters · filed 2018-11-09 | $36.25M derived: sum of 3 quarters · filed 2018-11-09 | $50.90M 10-K · filed 2018-03-15 | ||||||||
| 2017-09-30 | $9.46M 10-Q · filed 2018-11-09 | $27.48M derived: sum of 2 quarters · filed 2018-11-09 | $42.13M 10-Q · filed 2018-11-09 | $64.61M derived: sum of 4 quarters · filed 2018-11-09 | ||||||||
| 2017-06-30 | $18.01M 10-Q · filed 2018-08-09 | $32.66M 10-Q · filed 2018-08-09 | $55.15M derived: sum of 3 quarters · filed 2018-08-09 | $74.31M derived: sum of 4 quarters · filed 2018-08-09 | ||||||||
| 2017-03-31 | $14.65M 10-Q · filed 2018-05-03 | $37.14M derived: sum of 2 quarters · filed 2018-05-03 | $56.30M derived: sum of 3 quarters · filed 2018-05-03 | $74.73M derived: sum of 4 quarters · filed 2018-05-03 | ||||||||
| 2016-12-31 | $22.49M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $41.65M derived: sum of 2 quarters · filed 2018-03-15 | $60.08M derived: sum of 3 quarters · filed 2018-03-15 | $81.67M 10-K · filed 2018-03-15 | ||||||||
| 2016-09-30 | $19.16M 10-Q · filed 2017-11-02 | $37.59M derived: sum of 2 quarters · filed 2017-11-02 | $59.18M 10-Q · filed 2017-11-02 | $79.57M derived: sum of 4 quarters · filed 2018-03-15 | ||||||||
| 2016-06-30 | $18.43M 10-Q · filed 2017-08-03 | $40.02M 10-Q · filed 2017-08-03 | $60.41M derived: sum of 3 quarters · filed 2018-03-15 | $78.26M derived: sum of 4 quarters · filed 2018-03-15 | ||||||||
| 2016-03-31 | $21.59M 10-Q · filed 2017-05-09 | $41.98M derived: sum of 2 quarters · filed 2018-03-15 | $59.83M derived: sum of 3 quarters · filed 2018-03-15 | $77.03M derived: sum of 4 quarters · filed 2018-03-15 | ||||||||
| 2015-12-31 | $20.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $38.24M derived: sum of 2 quarters · filed 2018-03-15 | $55.45M derived: sum of 3 quarters · filed 2018-03-15 | $72.28M 10-K · filed 2018-03-15 | ||||||||
| 2015-09-30 | $17.85M 10-Q · filed 2016-11-03 | $35.05M derived: sum of 2 quarters · filed 2016-11-03 | $51.88M 10-Q · filed 2016-11-03 | $70.17M derived: sum of 4 quarters · filed 2017-03-02 | ||||||||
| 2015-06-30 | $17.20M 10-Q · filed 2016-08-04 | $34.03M 10-Q · filed 2016-08-04 | $52.32M derived: sum of 3 quarters · filed 2017-03-02 | $64.72M derived: sum of 4 quarters · filed 2017-03-02 | ||||||||
| 2015-03-31 | $16.83M 10-Q · filed 2016-05-05 | $35.12M derived: sum of 2 quarters · filed 2017-03-02 | $47.52M derived: sum of 3 quarters · filed 2017-03-02 | $57.11M derived: sum of 4 quarters · filed 2017-03-02 | ||||||||
| 2014-12-31 | $18.29M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $30.69M derived: sum of 2 quarters · filed 2017-03-02 | $40.28M derived: sum of 3 quarters · filed 2017-03-02 | $47.93M 10-K · filed 2017-03-02 | ||||||||
| 2014-09-30 | $12.40M 10-Q · filed 2015-11-05 | $21.99M derived: sum of 2 quarters · filed 2015-11-05 | $29.64M 10-Q · filed 2015-11-05 | $40.66M derived: sum of 4 quarters · filed 2016-02-26 | ||||||||
| 2014-06-30 | $9.60M 10-Q · filed 2015-08-10 | $17.25M 10-Q · filed 2015-08-10 | $28.26M derived: sum of 3 quarters · filed 2016-02-26 | $35.18M derived: sum of 4 quarters · filed 2016-02-26 | ||||||||
| 2014-03-31 | $7.65M 10-Q · filed 2015-05-11 | $18.66M derived: sum of 2 quarters · filed 2016-02-26 | $25.59M derived: sum of 3 quarters · filed 2016-02-26 | $31.61M derived: sum of 4 quarters · filed 2016-02-26 | $52.94M 10-Q · filed 2014-05-08 | |||||||
| 2013-12-31 | $11.01M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $17.94M derived: sum of 2 quarters · filed 2016-02-26 | $23.96M derived: sum of 3 quarters · filed 2016-02-26 | $29.13M 10-K · filed 2016-02-26 | $45.29M 10-K · filed 2014-02-27 | |||||||
| 2013-09-30 | $6.92M 10-Q · filed 2014-11-10 | $12.95M derived: sum of 2 quarters · filed 2014-11-10 | $18.12M 10-Q · filed 2014-11-10 | $22.33M derived: sum of 4 quarters · filed 2015-03-16 | $34.27M 10-Q · filed 2013-11-13 | |||||||
| 2013-06-30 | $6.02M 10-Q · filed 2014-08-07 | $11.20M 10-Q · filed 2014-08-07 | $15.40M derived: sum of 3 quarters · filed 2015-03-16 | $18.52M derived: sum of 4 quarters · filed 2015-03-16 | $27.35M 10-Q · filed 2013-08-13 | |||||||
| 2013-03-31 | $5.17M 10-Q · filed 2014-05-08 | $9.38M derived: sum of 2 quarters · filed 2015-03-16 | $12.50M derived: sum of 3 quarters · filed 2015-03-16 | $15.74M derived: sum of 4 quarters · filed 2015-03-16 | $21.33M 10-Q · filed 2013-05-15 | |||||||
| 2012-12-31 | $4.21M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $7.33M derived: sum of 2 quarters · filed 2015-03-16 | $10.56M derived: sum of 3 quarters · filed 2015-03-16 | $13.53M 10-K · filed 2015-03-16 | $16.15M 10-K · filed 2013-02-25 | |||||||
| 2012-09-30 | $3.12M 10-Q · filed 2013-11-13 | $6.35M derived: sum of 2 quarters · filed 2013-11-13 | $9.32M 10-Q · filed 2013-11-13 | $11.94M 10-Q · filed 2012-11-13 | ||||||||
| 2012-06-30 | $3.23M 10-Q · filed 2013-08-13 | $6.20M 10-Q · filed 2013-08-13 | $8.82M 10-Q · filed 2012-08-14 | |||||||||
| 2012-03-31 | $2.97M 10-Q · filed 2013-05-15 | |||||||||||
| 2011-12-31 | $2.62M 10-K · filed 2014-02-27 | |||||||||||
| 2011-09-30 | $774.00K 10-Q · filed 2012-11-13 | $1.18M 10-Q · filed 2012-11-13 | ||||||||||
| 2011-06-30 | $410.00K 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |